HIGHLIGHTS
- who: Chi-Yuan Cheng et al. from the Department of Pharmacy, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan have published the research: Precision Medicine in Cholangiocarcinoma: Past, Present, and Future, in the Journal: Life 2022, 829 of 20/05/2022
- what: The PFS benefit from ivosidenib largely results from a DCR of 53.2%; therefore, enhancing the activity of such inhibitors by modifying the structure or combination therapy should be a goal in patients with IDH-mutant CC.
- how: Some of the genetic alterations currently have no clinical features therefore the authors . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.